Showing results (31-40 of 993) with videos related to
Sort By:
Pageof 100
Plos One|March 28, 2024
p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesisÖzgün Le Roux, Jeffery I Everitt, Christopher M CounterNature Communications|November 15, 2014
Decreased tumorigenesis in mice with a Kras point mutation at C118Lu Huang, John Carney, Diana M Cardona, et al.Oncogene|October 10, 2002
Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cellsNesrin M Hamad, Soma S R Banik, Christopher M CounterThe Journal of Urology|July 11, 2003
In vivo regulation of hTERT expression and telomerase activity by androgenChuanhai Guo, Blaine N Armbruster, David T Price, et al.Molecular and Cellular Biology|April 17, 2003
Putative telomere-recruiting domain in the catalytic subunit of human telomeraseBlaine N Armbruster, Katherine T Etheridge, Dominique Broccoli, et al.Frontiers in Cell and Developmental Biology|March 16, 2026
Loss of inducible nitric oxide synthase promotes Kras/Pten-driven lung tumorigenesisZahra Kabiri, Hamed Zaribafzadeh, Sara Raji, et al.Cancer Research|October 8, 2017
Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 InhibitorsDonita C Brady, Matthew S Crowe, Danielle N Greenberg, et al.Cancer Research|November 4, 2005
A network of genetic events sufficient to convert normal human cells to a tumorigenic stateS DiSean Kendall, Corinne M Linardic, Stacey J Adam, et al.Nature|March 18, 2008
Tumour maintenance is mediated by eNOSKian-Huat Lim, Brooke B Ancrile, David F Kashatus, et al.Oncotarget|June 11, 2016
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancerNicole L K Pershing, Chi-Fu Jeffrey Yang, MengMeng Xu, et al.Pageof 100